Sign in
CompletedNo phase

The Role of the Glymphatic System Avaluated Thourgh mr Imaging in the Diagnosis and Management of NPH

Key facts

Who runs it
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
29 people enrolled
Started
15 Jun 2021
Ended
31 Dec 2024
Type of study
Observational, 2 groups
Record updated
11 February 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • clinical and radiological diagnosis of probable NPH according to existing guidelines
  • age of over 50 years

Who cannot take part

  • previous neurosurgical interventions on the brain of any type
  • inability to undergo MR
  • diagnosis of any other neurological pathology, particularly neurodegenerative or neuroinflammatory
  • inability to undergo general anaesthesia

Other criteria

  • Suspected NPH patients according to the following:

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to evaluate the role of DTI-ALPS in the diagnostic and therapeutic management of NPH

Read full original descriptionShow less

The main questions it aims to answer are:

* Whether the glymphatic system (GS) is actually impaired in NPH * Whether DTI-ALPS index can predict the positive response to tap test (TT) and to ventriculo-peritoneal shunt (VPS) surgery.

A healthy control group of patients (HC group) matched for age with the study group, will undergo MR with DTI-ALPS study

The 2 groups in the trial

  • Study group

    Patients attending the NPH outpatient clinic were prospectively enrolled in the study. The inclusion criteria were: (i) clinical and radiological diagnosis of probable NPH according to existing guidelines and (ii) age of over 50 years. Exclusion criteria were: (i) inability to undergo MR; (ii) a diagnosis of any other neurological pathology, particularly neurodegenerative or neuroinflammatory; (iii) previous neurosurgical interventions on the brain of any type; (iv) inability to undergo general anaesthesia.

  • Control group

    A healthy control group of patients (HC group) matched for age with the IR group, underwent MR with DTI-ALPS study. Exclusion criteria for this group were: (i) a previous diagnosis of any neurological disorder of any type. (ii) a history of neurosurgical intervention of any kind; and (iii) a prior diagnosis of malignancy of any type.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 February 2026